GSK expects to deliver annual sales and profit growth towards the top end of its forecasts after beating second-quarter ...

British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 ...

UK-listed pharmaceutical company plans to bring four more speciality medicines to late-stage clinical trials this year ...

GSK plc GSK reported second-quarter 2025 core earnings of $1.23 per American depositary share (ADS), which beat the Zacks ...

FTSE 100 reaction as HSBC sees profits drop, Nationwide launches benefits line - Stock market news and latest business and ...

The FTSE 100 has ticked up this morning after what became a wobbly session on Monday, with a stack of fresh earnings updates helping traders early on Tuesday. Entain and Games Workshop are leading ...

Swiss banking giant UBS said Wednesday that its net profit doubled in the second quarter thanks to a surge in transactions during global market volatility.Despite the ...

HSBC Holdings PLC (LSE:LON: HSBA) has reported a 29% plunge in profit before tax to $6.3 billion for the second quarter, but has unveiled another $3 billion share buyback and $0.10 quarterly dividend ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

Natalie Weger - profile from The Wall Street Journal. News, articles, biography and photos.

The U.S. FDA's panel of independent advisers on Thursday recommended against GSK's blood cancer drug Blenrep, citing concerns about previously documented risks of eye-related side effects, sending ...